A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Simple Search

You could also try: differ (84), diverge (7), contrast (149), fluctuate (25), disagree (11), change (1000)

Chimeric antigen receptor T-cell (CAR-T) therapy discharge medicines - patient information

Description
This factsheet explains what chimeric antigen receptor T-cell (CAR-T) therapy is and what it involves so you know what
Url
/Media/UHS-website-2019/Patientinformation/Cancercare/Chimeric-antigen-receptor-T-cell-CAR-T-therapy-discharge-meds-3635-PIL.pdf

Welcome to the TAVI clinic - patient information

Description
Information about transcatheter aortic valve implantation (TAVI) - a procedure to replace a faulty aortic (heart) valve via a thin plastic tube
Url
/Media/UHS-website-2019/Patientinformation/Cardiovascular-and-thoracic/Welcome-to-the-TAVI-clinic-3352-PIL.pdf

mini-RCHOP 21

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-DOXORUBICIN-PREDNISOLONE-RITUXIMAB-VINCRISTINE (mini-RCHOP 21) Regimen   Lymphoma – mini-RCHOP (21)-Cyclophosphamide-Doxorubicin-PrednisoloneRituximab-Vincristine Indication
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/mini-RCHOP-21.pdf

Annual report 2021-2022

Description
2021/22 Incorporating the quality report University Hospital Southampton NHS Foundation Trust Annual Report and Accounts 2021/22 Presented to Parliament
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/Annual-report-2021-2022.pdf

IPD-Dexamethasone-Isatuximab-Pomalidomide

Description
Chemotherapy Protocol Myeloma Isatuximab-Dexamethasone (40)-Pomalidomide Regimen • Myeloma – Isatuximab-Dexamethasone (40)-Pomalidomide Indication • Isatuximab is indicated where; - the patient has
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/IPD-Dexamethasone-Isatuximab-Pomalidomide.pdf

PV-CHP Cyclophosphamide-doxorubicin-polatuzumab vedotin -prednisolone

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-DOXORUBICIN-POLATUZUMAB VEDOTIN-PREDNISOLONE- RITUXIMAB Regimen • Lymphoma – Cyclophosphamide-doxorubicin-polatuzumab vedotin -prednisolone – rituximab Indication • Previously untreated diffuse
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/PV-CHP-Cyclophosphamide-doxorubicin-polatuzumab-vedotin-prednisolone.pdf

InP methotrexate

Description
Chemotherapy Protocol LYMPHOMA METHOTREXATE Inpatient Regimen Regimen • Lymphoma – InP-Methotrexate Indication • Non-Hodgkin’s Lymphoma (N
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-methotrexate.pdf

DVd Weekly Daratumumab-Bortezomib-Dexamethasone Cycles 1 to 8

Description
Chemotherapy Protocol Myeloma DVd (Weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 1 to 8) Regimen • Myeloma – Bortezomib (weekly)-Daratumumab-Dexamethasone Indication • Daratumumab in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Weekly-Daratumumab-Bortezomib-Dexamethasone-Cycles-1-to-8.pdf

Chlorambucil_7_Rituximab

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia (CLL) Chlorambucil (7 day)-Rituximab Regimen • CLL – Chlorambucil (7 day)-Rituximab Indication • Treatment of CLL in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Chlorambucil-7-Rituximab.pdf

Chlorambucil_14_Rituximab

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia (CLL) Chlorambucil (14 day)-Rituximab Regimen • CLL – Chlorambucil (14 day)-Rituximab Indication • Treatment of CLL in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Chlorambucil-14-Rituximab.pdf
11 to 20 of 326
Previous 1 2 3 4 5 … Next